Aprea Therapeutics (APRE) Operating Expenses (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Operating Expenses of $3.4 million for Q1 2026, down 19.25% year-over-year from $4.2 million in Q1 2025, and up 29.62% quarter-over-quarter from $2.6 million in Q4 2025.
Aprea Therapeutics (APRE) Operating Expenses (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Operating Expenses for 9 consecutive years, with $3.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 19.25% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $12.7 million (down 23.2% YoY), while the FY2025 annual figure was $13.5 million, down 14.55% from the prior year.
- Operating Expenses improved to $3.4 million in Q1 2026 per APRE's latest filing, from $2.6 million in the prior quarter.
- Across five years, Operating Expenses topped out at $98.5 million in Q2 2022 and bottomed at $2.6 million in Q4 2025.
- Historically, Operating Expenses has averaged $9.5 million across 5 years, with a median of $3.8 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Expenses jumped 884.89% — and 2023, when it slumped 96.04%.
- Aprea Therapeutics' Operating Expenses stood at $2.7 million in 2022, then jumped by 39.12% to $3.7 million in 2023, then dropped by 6.97% to $3.4 million in 2024, then declined by 22.89% to $2.6 million in 2025, then grew by 29.62% to $3.4 million in 2026.
- Business Quant data shows APRE's Operating Expenses at $3.4 million in Q1 2026, $2.6 million in Q4 2025, and $3.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Aprea Therapeutics | 34.28 Mn | 34.28 Mn | - | 4.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.03 Mn |
| Mar 31, 2026 | 3.43 Mn |
| Dec 31, 2025 | 2.65 Mn |
| Sep 30, 2025 | 3.12 Mn |
| Jun 30, 2025 | 3.51 Mn |
| Mar 31, 2025 | 4.25 Mn |
| Dec 31, 2024 | 3.43 Mn |
| Sep 30, 2024 | 4.45 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Mar 31, 2024 | 3.53 Mn |
| Dec 31, 2023 | 3.69 Mn |
| Sep 30, 2023 | 3.84 Mn |
| Jun 30, 2023 | 3.90 Mn |
| Mar 31, 2023 | 4.62 Mn |
| Dec 31, 2022 | 2.65 Mn |
| Sep 30, 2022 | 4.20 Mn |
| Jun 30, 2022 | 98.47 Mn |
| Mar 31, 2022 | 8.07 Mn |
| Dec 31, 2021 | 7.83 Mn |
| Sep 30, 2021 | 9.43 Mn |